All Stories

  1. Aminochrome, a Key Molecule in the Loss of Dopaminergic Neurons Containing Neuromelanin in Idiopathic Parkinson's Disease
  2. Aminochrome-Induced Disruption of Autophagosome-Lysosome Fusion: Implications for Protein Aggregation in Parkinson’s Disease
  3. A Potential Role of Natural Bioactive Compounds Found in Food in the Prevention of Idiopathic Parkinson’s Disease
  4. On the Role of Iron in Idiopathic Parkinson’s Disease
  5. Why are neuromelanin-containing dopaminergic neurons lost in idiopathic Parkinson’s disease?
  6. Single-neuron neurodegeneration as a degenerative model for Parkinson’s disease
  7. A Preclinical Model for Parkinson’s Disease Based on Transcriptional Gene Activation via KEAP1/NRF2 to Develop New Antioxidant Therapies
  8. Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase
  9. Generation of nonviral integration-free human iPS cell line KISCOi001-A from normal human fibroblasts, under defined xeno-free and feeder-free conditions
  10. Cellular Trafficking of Glutathione Transferase M2-2 Between U373MG and SHSY-S7 Cells is Mediated by Exosomes
  11. State and perspectives on flavonoid neuroprotection against aminochrome-induced neurotoxicity
  12. The Flavonoid Agathisflavone from Poincianella pyramidalis Prevents Aminochrome Neurotoxicity
  13. The importance of choosing a preclinical model that reflects what happens in Parkinson's disease
  14. DT-Diaphorase Prevents Aminochrome-Induced Lysosome Dysfunction in SH-SY5Y Cells
  15. Can we conclude a potential therapeutic action for Parkinson’s disease by using postmortem tissue and a preclinical model based on an exogenous neurotoxin?
  16. P1‐159: RARE VARIANTS IN PLCG2, ABI3, AND TREM2 GENES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE IN AN ARGENTINIAN SAMPLE: IS IT A EUROPEAN HERITAGE?
  17. Comment on: “Activating Autophagy as a Therapeutic Strategy for Parkinson’s Disease”
  18. Aminochrome decreases NGF, GDNF and induces neuroinflammation in organotypic midbrain slice cultures
  19. Aminochrome Induces Irreversible Mitochondrial Dysfunction by Inducing Autophagy Dysfunction in Parkinson's Disease
  20. Neurotoxins as Preclinical Models for Parkinson’s Disease
  21. KM-34, a Novel Antioxidant Compound, Protects against 6-Hydroxydopamine-Induced Mitochondrial Damage and Neurotoxicity
  22. The Importance of Mitophagy in Maintaining Mitochondrial Function in U373MG Cells. Bafilomycin A1 Restores Aminochrome-Induced Mitochondrial Damage
  23. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
  24. Aminochrome induces microglia and astrocyte activation
  25. Knockdown of Myo-Inositol Transporter SMIT1 Normalizes Cholinergic and Glutamatergic Function in an Immortalized Cell Line Established from the Cerebral Cortex of a Trisomy 16 Fetal Mouse, an Animal Model of Human Trisomy 21 (Down Syndrome)
  26. Aminochrome as preclinical model for Parkinson's disease
  27. Commentary: Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?
  28. DT-diaphorase Protects Against Autophagy Induced by Aminochrome-Dependent Alpha-Synuclein Oligomers
  29. New preclinical model are required to discover neuroprotective compound in Parkinson’s disease
  30. On the Role of Mining Exposure in Epigenetic Effects in Parkinson’s Disease
  31. On the Role of DT-Diaphorase Inhibition in Aminochrome-Induced Neurotoxicity In Vivo
  32. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson’s Disease?
  33. Autophagy protects against neural cell death induced by piperidine alkaloids present in Prosopis juliflora (Mesquite)
  34. On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease
  35. Corrigendum: Commentary: Evaluation of Models of Parkinson's Disease
  36. DT-diaphorase protects astrocytes from aminochrome-induced toxicity
  37. Commentary: A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease
  38. Commentary: Evaluation of Models of Parkinson's Disease
  39. Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson’s disease
  40. Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases
  41. Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
  42. Erratum
  43. The need of a new and more physiological preclinical model for Parkinson’s disease
  44. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
  45. Aminochrome Toxicity is Mediated by Inhibition of Microtubules Polymerization Through the Formation of Adducts with Tubulin
  46. Neurotoxin Mechanisms and Processes Relevant to Parkinson’s Disease: An Update
  47. DT-Diaphorase Prevents Aminochrome-Induced Alpha-Synuclein Oligomer Formation and Neurotoxicity
  48. A new mechanism for protection of dopaminergic neurons mediated by astrocytes
  49. Molecular and Neurochemical Mechanisms Dopamine Oxidation To O-Quinones in Parkinson’s Disease Pathogenesis
  50. Glutathione Transferase-M2-2 Secreted from Glioblastoma Cell Protects SH-SY5Y Cells from Aminochrome Neurotoxicity
  51. Protective and toxic roles of dopamine in Parkinson's disease
  52. Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction
  53. Advances in Stem Cell Research for Parkinson Disease
  54. Dopamine and L-dopa as Selective Endogenous Neurotoxins
  55. Mechanisms of Dopamine Oxidation and Parkinson’s Disease
  56. RCSN Cell System for Identifying Dopaminergic Neurotoxicity
  57. One-Electron Reduction of 6-Hydroxydopamine Quinone is Essential in 6-Hydroxydopamine Neurotoxicity
  58. Frequency of the D620N Mutation in VPS35 in Parkinson Disease
  59. Erratum to: Protective Effects of Nicotine Against Aminochrome-Induced Toxicity in Substantia Nigra Derived Cells: Implications for Parkinson’s Disease
  60. Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity
  61. Protective Effects of Nicotine Against Aminochrome-Induced Toxicity in Substantia Nigra Derived Cells: Implications for Parkinson’s Disease
  62. Guidelines for the use and interpretation of assays for monitoring autophagy
  63. Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy
  64. The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1
  65. Dopamine Oxidation and Autophagy
  66. The role of metal ions in dopaminergic neuron degeneration in Parkinsonism and Parkinson’s disease
  67. Altered Voltage Dependent Calcium Currents in a Neuronal Cell Line Derived From the Cerebral Cortex of a Trisomy 16 Fetal Mouse, an Animal Model of Down Syndrome
  68. Lrrk2 p.Q1111H substitution and Parkinson’s disease in Latin America
  69. ChemInform Abstract: The Role of Metal Ions in Dopaminergic Neuron Degeneration in Parkinsonism and Parkinson′s Disease
  70. The role of metal ions in dopaminergic neuron degeneration in Parkinsonism and Parkinson’s disease
  71. Autophagy Protects Against Aminochrome-Induced Cell Death in Substantia Nigra-Derived Cell Line
  72. Catecholaminergic Cell Lines for the Study of Dopamine Metabolism and Neurotoxicity
  73. Association of Parkinson disease to PARK16 in a Chilean sample
  74. Stable Expression of Short Interfering RNA for DT-Diaphorase Induces Neurotoxicity
  75. Erratum to: Aminochrome Induces Disruption of Actin, Alpha-, and Beta-Tubulin Cytoskeleton Networks in Substantia-Nigra-Derived Cell Line
  76. Aminochrome Induces Disruption of Actin, Alpha-, and Beta-Tubulin Cytoskeleton Networks in Substantia-Nigra-Derived Cell Line
  77. Diagnóstico genético disponible para la enfermedad de huntington en chile
  78. IV Neurotoxicity Society Meeting: Neurochemical Mechanisms of Neurodegenerative Disorders
  79. Molecular and Neurochemical Mechanisms in PD Pathogenesis
  80. Copper·Dopamine Complex Induces Mitochondrial Autophagy Preceding Caspase-independent Apoptotic Cell Death
  81. Chapter 4 Molecular Aspects of Neurotoxins in Dopaminergic Neurons
  82. The catecholaminergic RCSN-3 cell line: A model to study dopamine metabolism
  83. Copper Neurotoxicity in Rat Substantia Nigra and Striatum Is Dependent on DT-Diaphorase Inhibition
  84. Erratum
  85. Effect of the knockdown of amyloid precursor protein on intracellular calcium increases in a neuronal cell line derived from the cerebral cortex of a trisomy 16 mouse
  86. Botulinum neurotoxin: Evolution from poison, to research tool - onto medicinal therapeutic and future pharmaceutical panacea
  87. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease
  88. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson’s disease
  89. Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component
  90. Inhibition of VMAT-2 and DT-Diaphorase Induce Cell Death in a Substantia Nigra-Derived Cell LineAn Experimental Cell Model for Dopamine Toxicity Studies
  91. Neurotoxins and neurotoxicity mechanisms. an overview
  92. Knockdown of amyloid precursor protein normalizes cholinergic function in a cell line derived from the cerebral cortex of a trisomy 16 mouse: An animal model of down syndrome
  93. Dopamine-Dependent Iron Toxicity in Cells Derived from Rat Hypothalamus
  94. Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra
  95. Cell Lines as In Vitro Models for Drug Screening and Toxicity Studies
  96. On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation
  97. Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor
  98. Neurotoxins and neurotoxic species implicated in neurodegeneration
  99. Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats
  100. Inhibition of DT-Diaphorase potentiates thein vivo neurotoxic effect of intranigral injection of salsolinol in rats
  101. MPP+-induced degeneration is potentiated by dicoumarol in cultures of the RCSN-3 dopaminergic cell line. Implications of neuromelanin in oxidative metabolism of dopamine neurotoxicity
  102. Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. A review
  103. Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra
  104. Establishment and characterization of immortalized neuronal cell lines derived from the spinal cord of normal and trisomy 16 fetal mice, an animal model of Down syndrome
  105. Neurotoxicological and neuroprotective elements in Parkinson’s disease
  106. Inhibition of DT-diaphorase is a requirement for Mn3+ to produce a 6-OH-dopamine like rotational behaviour
  107. Neurotoxicity of some MAO inhibitors in adult rat hypothalamic cell culture
  108. Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line
  109. Possible Role of Salsolinol Quinone Methide in the Decrease of RCSN-3 Cell Survival
  110. THE PRICE OF DEVELOPMENT IN CHILE
  111. The possible role of one-electron reduction of aminochrome in the neurodegenerative process of the dopaminergic system
  112. Glutathione Transferase M2-2 Catalyzes Conjugation of Dopamine and Dopa o-Quinones
  113. Reduction of Brain Antioxidant Defense Upon Treatment with Butylated Hydroxyanisole (BHA) and Sudan III in Syrian Golden Hamster
  114. Regioselectivity and Reversibility of the Glutathione Conjugation of Quercetin Quinone Methide
  115. Role of redox cycling and activation by DT-diaphorase in the cytotoxicity of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB-1954) and its analogs
  116. Interplay Between CYP3A-Mediated Metabolism and Polarized Efflux of Terfenadine and Its Metabolites in Intestinal Epithelial Caco-2 (TC7) Cell Monolayers
  117. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product
  118. DT-diaphorase catalyzes N-denitration and redox cycling of tetryl
  119. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects
  120. Quantitative structure activity relationships for the conversion of nitrobenzimidazolones and nitrobenzimidazoles by DT-diaphorase: implications for the kinetic mechanism
  121. Nitrobenzimidazoles as Substrates for DT-Diaphorase and Redox Cycling Compounds: Their Enzymatic Reactions and Cytotoxicity
  122. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes
  123. Effects of Four Organohalogen Environmental Contaminants on Cytochrome P450 Forms That Catalyze 4- and 2-Hydroxylation of Estradiol in the Rat Liver
  124. Human Class Mu Glutathione Transferases, in Particular Isoenzyme M2-2, Catalyze Detoxication of the Dopamine Metabolite Aminochrome
  125. The two-electron quinone reductase DT-diaphorase generates and maintains the antioxidant (reduced) form of coenzyme Q in membranes
  126. DT-Diaphorase Maintains the Reduced State of Ubiquinones in Lipid Vesicles thereby Promoting their Antioxidant Function
  127. Peroxidase Activity of Liver Microsomal Vitamin D 25-Hydroxylase and Cytochrome P450 1A2 Catalyzes 25-Hydroxylation of Vitamin D3and Oxidation of Dopamine to Aminochrome
  128. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems.
  129. Effects of Superoxide Dismutase and Catalase during Reduction of Adrenochrome by DT-Diaphorase and NADPH-Cytochrome P450 Reductase
  130. Studies on the mode of action of the herbicidal effect of 2,4,5-trichlorophenoxyacetic acid on germinating Norway spruce
  131. Superoxide Dismutase and Catalase Enhance Autoxidation during One-Electron Reduction of Aminochrome by NADPH-Cytochrome P-450 Reductase
  132. Superoxide dismutase and catalase prevent the formation of reactive oxygen species during reduction of cyclized dopa ortho-quinone by DT-diaphorase
  133. The protective effect of superoxide dismutase and catalase against formation of reactive oxygen species during reduction of cyclized norepinephrine ortho-quinone of DT-diaphorase
  134. Activity and immunohistochemistry of DT-diaphorase in hamster and human kidney tumours
  135. A new direct method for determining superoxide dismutase activity by measuring hydrogen peroxide formation
  136. The Effect of 5OH-1,4-Naphthoquinone on Norway Spruce Seeds during Germination
  137. The cytotoxic effects of 5-OH-1,4-naphthoquinone and 5,8-diOH-1,4-naphthoquinone on doxorubicin-resistant human leukemia cells (HL-60)
  138. Separation and characterization of isoforms of DT-diaphorase from rat liver cytosol
  139. Oxygen toxicity in the nervous tissue: Comparison of the antioxidant defense of rat brain and sciatic nerve
  140. Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve
  141. The levels of quinone reductases, superoxide dismutase and glutathione-related enzymatic activities in diethylstilbestrol-induced carcinogenesis in the kidney of male Syrian golden hamsters
  142. On the mechanism of the Mn3+-induced neurotoxicity of dopamine: Prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase
  143. DT-diaphorase-catalyzed two-electron reduction of various p-benzoquinone- and 1,4-naphthoquinone epoxides
  144. Effect of superoxide dismutase on the autoxidation of various hydroquinones—A possible role of superoxide dismutase as a superoxide: Semiquinone oxidoreductase
  145. DT-diaphorase-catalyzed two electron reduction of quinone epoxides
  146. Dicoumarol-sensitive glucuronidation of benzo(a)pyrene metabolites in rat liver microsomes